Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: BMS-986497, Azacitidine, Venetoclax; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: New Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Infections, Bacterial
Interventions: GSK1322322 Initial fit for purpose tablets, GSK1322322 over granulated tablets, GSK1322322 intended commercial tablets, Placebo tablets, 13C-GSK1322322 stable isotope powder, GSK1322322 for injection, Placebo injection; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Participants
Interventions: NAL ER, Pirfenidone, Nintedanib; Drug
Lead sponsor: Trevi Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypertriglyceridemia
Interventions: MAR001, Placebo; Drug
Lead sponsor: Marea Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 26
States / cities: Anniston, Alabama • Mobile, Alabama • Little Rock, Arkansas + 23 more

Conditions: Postpartum Depression
Interventions: SAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 27
States / cities: Little Rock, Arkansas • Beverly Hills, California • Oceanside, California + 24 more

Conditions: Mild Cognitive Impairment
Interventions: Tiempo Juntos Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 55 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Health Information Technology, Health Information Exchange, Virtual Health Record, Health Care Utilization
Interventions: Virtual Health Record (VHR); Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 218,766 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 3
States / cities: Buffalo, New York • New York, New York • Rochester, New York

Conditions: Colorectal Carcinoma
Interventions: Best Practice, Communication Intervention, Interview; Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 1,680 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Hepatitis C Infection
Interventions: Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin, Ombitasvir mini tablet, Paritaprevir mini tablet, Ritonavir mini tablet, Dasabuvir mini tablet, Ribavirin solution; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 7 more

Conditions: Constipation
Interventions: Prucalopride, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 41
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 32 more

Conditions: Child Development
Interventions: Training for ACEs and study procedures, Training on study procedures; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chamblee, Georgia

Conditions: Lymphoma, B-Cell
Interventions: CC-220, Polatuzumab vedotin, Rituximab, Tafasitamab, Gemcitabine, Cisplatin, Dexamethasone, Bendamustine, Lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Sioux Falls, South Dakota

Conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: ONO-7018; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Santa Monica, California • Kansas City, Missouri • Florham Park, New Jersey + 7 more

Conditions: Volunteers, Healthy Volunteers, Human Volunteers, Normal Volunteers
Interventions: entinostat, Omeprazole, Famotidine; Drug · Dietary Supplement
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: HIV-1 Infection
Interventions: Vesatolimod, Placebo, ART; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Ft. Pierce, Florida + 3 more

Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Interventions: ION251; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: La Jolla, California • Los Angeles, California • Detroit, Michigan + 2 more

Conditions: Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Interventions: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: San Francisco, California • Boston, Massachusetts • Columbus, Ohio + 1 more

Conditions: Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers
Interventions: simlukafusp alfa, Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Gemcitabine, Vinorelbine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: San Francisco, California • Newnan, Georgia

Conditions: Systemic Mastocytosis With an Associated Hematologic Neoplasm
Interventions: Avapritinib, Decitabine, Decitabine/Cedazuridine; Drug · Combination Product
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Phoenix, Arizona • Palo Alto, California • Tampa, Florida + 4 more

Conditions: Substance Use Disorders, Insomnia
Interventions: Brief Behavioral Therapy for Insomnia (BBTI); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumor
Interventions: ORIC-101, Nab-paclitaxel; Drug
Lead sponsor: ORIC Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 12
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Atrial Fibrillation
Interventions: Catheter ablation; Procedure
Lead sponsor: Texas Cardiac Arrhythmia Research Foundation; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Metastatic Breast Cancer
Interventions: JNJ-101684362 (HLD-0117); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: New Haven, Connecticut • Sarasota, Florida • Boston, Massachusetts + 3 more

Conditions: Adenoidectomy, Functional Endoscopic Sinus Surgery (FESS), Turbinate Surgery
Interventions: Oxymetazoline; Drug
Lead sponsor: Richard Cartabuke; Other
Eligibility: 2 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects

A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

A Physical Activity Intervention to Promote Cognitive Health, Cardiovascular Health and Sleep in Older Latinos

Assessing the Impact of Health Information Exchange (HIE) on Healthcare Utilization

Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

A Study of Prucalopride For Functional Constipation in Children and Teenagers

Caregiver Adverse Childhood Experiences (ACEs) in Pediatric Primary Care

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects

Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers

A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Avapritinib With Decitabine in Patients With SM-AHN

Feasibility of Brief Behavioral Therapy for Insomnia (BBTI) in SUD Recovery

Study of ORIC-101 in Combination With Anticancer Therapy

Impact of Anxiety on Cardiac Substrate Modification in Women With Atrial Fibrillation Undergoing Catheter Ablation

A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption